InvestSMART

Clarity Pharmaceuticals Ltd (ASX:CU6)

ALERT: Price-sensitive ASX Announcement for CU6
Current share price for CU6 : $2.120 -0.815 (-27.77%)+
Announcement
Release
30 Apr 2026 12:24PM
Price at Release
$2.935
Full Release
download
Summary
Clarity Pharmaceuticals Ltd, a clinical-stage radiopharmaceutical company, released its Quarterly Activity Report and Appendix 4C Cash Flow Report for the quarter ending 31 March 2026. The company reported a cash balance of $197.8 million and net cash outflows of $25.5 million for operating activities. Clarity highlighted advances in clinical trials, particularly the Co-PSMA trial which demonstrated superior detection of cancer lesions with 64Cu-SAR-bisPSMA over the standard 68Ga-PSMA-11. Management changes were noted, including new executive roles to bolster its regulatory and commercial capabilities. The report also detailed ongoing preparations for commercial operations and payments to related parties.
Key Points
  • Clarity Pharmaceuticals released its Quarterly Activity Report and Appendix 4C for the quarter ending 31 March 2026.
  • The company focuses on developing next-generation radiopharmaceuticals for cancer treatment.
  • Key trials include the Co-PSMA trial, showing improved cancer lesion detection using 64Cu-SAR-bisPSMA compared to 68Ga-PSMA-11.
  • The report highlights significant management changes, including new appointments such as Chris Horvath as Chief Commercial Officer and Juliane Foley as Vice President of Regulatory Affairs.
  • At the end of the quarter, Clarity had a cash balance of $197.8 million.
  • Net cash outflows for operating activities during the quarter were $25.5 million.
  • The company's commercial preparations include building out a supply chain for copper-64 and copper-67 production.
  • Payments to related parties totaled $675,443 for the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.